Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Müller, Berit Maria ^a   Jana, Lisa ^a   Kasajima, Atsuko ^c   Lehmann, Annika ^a   Prinzler, Judith ^a   Budczies, Jan ^a   Winzer, Klaus Jürgen ^a   Dietel, Manfred ^a   Weichert, Wilko ^b   Denkert, Carsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Institute of Pathology   (Germany)

^c TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Breast cancer; HDAC; Immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DISEASE PROGRESSION; FEMALE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASES; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TISSUE ARRAY ANALYSIS;

EID: 84876795104     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-215     Document Type: Article

References (28)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA: A Cancer Journal for Clinicians 2012, 62(1):10-29.
2. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006, 5(1):37-50. 10.1038/nrd1930, 16485345.
3. Kristensen LS, Nielsen HM, Hansen LL. Epigenetics and cancer treatment. Eur J Pharmacol 2009, 625(1-3):131-142.
4. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007, 26(37):5420-5432. 10.1038/sj.onc.1210610, 17694083.
5. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003, 370(Pt 3):737-749. 1223209, 12429021.
6. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett 2009, 280(2):168-176. 10.1016/j.canlet.2008.10.047, 19103471.
7. Schneider G, Krämer O, Schmid R, Saur D. Acetylation as a transcriptional control mechanism-HDACs and HATs in pancreatic ductal adenocarcinoma. J Gastrointest Cancer 2011, 42(2):85-92. 10.1007/s12029-011-9257-1, 21271301.
8. Sangha R, Lara PN, Mack PC, Gandara DR. Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier. Curr Opin Oncol 2009, 21(2):116-123. 10.1097/CCO.0b013e3283210489, 19532012.
9. Fritzsche FR, Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, Scholman K, Denkert C, Dietel M. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer 2008, 8:381. 10.1186/1471-2407-8-381, 2631013, 19099586.
10. Thurn KT, Thomas S, Moore A, Munster PN. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol 2011, 7(2):263-283. 10.2217/fon.11.2, 3127396, 21345145.
11. Linares A, Dalenc F, Balaguer P, Boulle N, Cavailles V. Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies?. J Biomed Biotechnol 2011, 2011:856985. 3004450, 21188173.
12. Higgins MJ, Stearns V. Pharmacogenetics of endocrine therapy for breast cancer. Annu Rev Med 2011, 62:281-293. 10.1146/annurev-med-070909-182545, 21226615.
13. Thomas S, Munster PN. Histone deacetylase inhibitor induced modulation of anti-estrogen therapy. Cancer Lett 2009, 280(2):184-191. 10.1016/j.canlet.2008.12.026, 19185986.
14. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 2001, 61(19):7025-7029.
15. Kurebayashi J. Resistance to endocrine therapy in breast cancer. Cancer Chemother Pharmacol 2005, 56:39-46.
16. Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, Wang SM, Herman JG, Davidson NE. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res 2000, 60(24):6890-6894.
17. Fortunati N, Bertino S, Costantino L, De Bortoli M, Compagnone A, Bandino A, Catalano MG, Boccuzzi G. Valproic acid restores ER alpha and antiestrogen sensitivity to ER alpha-negative breast cancer cells. Mol Cell Endocrinol 2010, 314(1):17-22. 10.1016/j.mce.2009.09.011, 19772891.
18. Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M, Rocha K, Wang HG, Richon V, Bhalla K. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. Clin Cancer Res 2005, 11(17):6382-6389. 10.1158/1078-0432.CCR-05-0344, 16144943.
19. Weichert W, Roske A, Niesporek S, Noske A, Buckendahl AC, Dietel M, Gekeler V, Boehm M, Beckers T, Denkert C. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 2008, 14(6):1669-1677. 10.1158/1078-0432.CCR-07-0990, 18347167.
20. Krusche CA, Wulfing P, Kersting C, Vloet A, Bocker W, Kiesel L, Beier HM, Alfer J. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat 2005, 90(1):15-23. 10.1007/s10549-004-1668-2, 15770522.
21. Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, Hamaguchi M, Hara Y, Kobayashi S, Iwase H. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*. Breast Cancer Res Treat 2005, 94(1):11-16. 10.1007/s10549-005-6001-1, 16172792.
22. Zhou Q, Atadja P, Davidson NE. Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. Cancer Biol Ther 2007, 6(1):64-69. 10.4161/cbt.6.1.3549, 17172825.
23. Biçaku E, Marchion DC, Schmitt ML, Münster PN. Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling. Cancer Res 2008, 68(5):1513-1519. 10.1158/0008-5472.CAN-07-2822, 18316616.
24. Travaglini L, Vian L, Billi M, Grignani F, Nervi C. Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status. Int J Biochem Cell Biol 2009, 41(1):225-234. 10.1016/j.biocel.2008.08.019, 18789398.
25. Duong V, Licznar A, Margueron R, Boulle N, Busson M, Lacroix M, Katzenellenbogen BS, Cavailles V, Lazennec G. ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors. Oncogene 2006, 25(12):1799-1806. 10.1038/sj.onc.1209102, 2034758, 16158045.
26. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail- Khan R, Rugo H, Moasser M. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 2011, 104(12):1828-1835. 10.1038/bjc.2011.156, 3111195, 21559012.
27. Suzuki J, Chen YY, Scott GK, Devries S, Chin K, Benz CC, Waldman FM, Hwang ES. Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res 2009, 15(9):3163-3171. 10.1158/1078-0432.CCR-08-2319, 19383825.
28. Marchion DC, Bicaku E, Turner JG, Schmitt ML, Morelli DR, Munster PN. HDAC2 regulates chromatin plasticity and enhances DNA vulnerability. Mol Cancer Ther 2009, 8(4):794-801. 10.1158/1535-7163.MCT-08-0985, 19372552.